
INDIANAPOLIS — Eli Lilly agreed on Monday to buy privately held biotech Calytrix Bio for up to $1.5 billion in cash, betting on an experimental antibody never tested in people that could one day change how two rare blood cancers are treated. The deal gives Lilly a preclinical programme aimed at essential thrombocythemia and myelofibrosis, diseases driven by a mutated protein called calreticulin for which no targeted therapy exists. It is Lilly's latest small-company purchase in a year of more than $30 billion in acquisitions, as it pushes beyond the diabetes and weight-loss medicines that made it the world's most valuable drug company.
Calytrix Bio announced on Monday that it had signed a definitive agreement to be acquired by Eli Lilly and Company. Under the terms, Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment and later payments if the programme hits agreed clinical and regulatory milestones. Neither company disclosed the upfront payment, and no closing timeline was given.
The target is a single experimental medicine: an investigational biparatopic antibody — built to bind two sites on the same target — aimed at mutant calreticulin, known as mCALR. It is designed to work against both Type 1 and Type 2 forms of the mutation, giving it what the company calls pan-mutant activity. The drug is still preclinical, tested only in laboratory and animal studies, and the first human trials are yet to begin.
Essential thrombocythemia and myelofibrosis are myeloproliferative neoplasms, cancers in which the bone marrow produces too many blood cells. In essential thrombocythemia, the marrow makes too many platelets, raising the risk of blood clots, strokes and bleeding. In myelofibrosis, the marrow becomes scarred and gradually stops working, leaving patients anaemic and exhausted, with the disease sometimes progressing to acute leukaemia.
Today's treatments mostly manage the consequences rather than the cause. Doctors use hydroxyurea and interferon to lower blood counts, and JAK inhibitors such as ruxolitinib can shrink an enlarged spleen and ease symptoms, but none removes the diseased cells. Mutant calreticulin appears on the surface of the diseased blood stem cells, giving a drug a specific target. Calytrix says its antibody can deplete the disease-driving mutant clone while sparing normal tissue and preserving healthy blood production.
The deal fits a clear pattern in Lilly's dealmaking this year. The Indianapolis drugmaker has spent more than $30 billion on acquisitions in 2026, its 14th or 15th purchase of the year, with most of the money going to private startups. The strategy is diversification: growth has been powered by its diabetes and weight-loss franchise, led by Mounjaro and Zepbound, and it is using that cash to build depth in cancer and blood disorders. Calytrix, founded only in 2025 by J.P. Morgan Life Sciences Private Capital, was still venture-funded a year ago.
It is also Lilly's second myelofibrosis deal of the year, after April's agreement to pay up to $2.3 billion for Ajax Therapeutics. Together, the two deals show Lilly building a dedicated position in myeloproliferative neoplasms. The price reflects how crowded the space has become: mutant calreticulin is one of the most attractive targets in blood-cancer research because it is present only on diseased cells, and several companies are racing to build drugs against it.
Brad Prosek, president and chief executive of Calytrix Bio, said the deal would speed up a programme his young company could not take through the clinic alone. "Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," Prosek said. "From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum."
Centerview Partners advised Calytrix, with Goodwin Procter as legal counsel, while Paul, Weiss advised Lilly. Neither side disclosed the upfront payment or a closing date, and no guidance was given on when the first human trial might start.
For patients, the deal puts one of the world's biggest drugmakers behind a new idea in a neglected corner of cancer. These diseases affect relatively few people, which has meant slower investment than in common cancers. A company of Lilly's size can fund the long, expensive trials required, and its arrival signals that mutant calreticulin is worth pursuing. For investors, it is a reminder that Lilly is spending its weight-loss profits aggressively — more than $30 billion of deals in a single year — on many smaller bets rather than one more blockbuster.
The deal must now close, and the companies have not said when that will happen. Once it does, Lilly will prepare the first human trials, a process that typically takes many months of manufacturing, safety testing and regulatory filings. Milestone payments fall due only if the drug clears agreed hurdles, so much of the $1.5 billion may never be paid if the programme stalls. See also Lilly's recent results, including its daily weight-loss pill cutting sleep apnoea episodes by up to 44% in Phase 3 trials and retatrutide halving knee arthritis pain in two major trials.
Up to $1.5 billion in cash, including an undisclosed upfront payment and further payments tied to clinical and regulatory milestones.
A preclinical biparatopic antibody targeting both Type 1 and Type 2 mutant calreticulin, for essential thrombocythemia and myelofibrosis. It has not yet been tested in people.
Rare blood cancers in which the bone marrow makes too many blood cells. Essential thrombocythemia causes excess platelets and clotting risk; myelofibrosis scars the marrow and can progress to leukaemia.
It appears on the surface of diseased blood stem cells, so a drug can attack the disease-driving cells while sparing healthy tissue.
Not for years, if it works at all. Lilly must first complete manufacturing and safety work, run Phase 1 trials, then larger studies before seeking approval.